Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Treated With Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate
This study showed that TAF had a hepatoprotective effect against HCC in patients with CHB, providing valuable guidance for clinicians in selecting the appropriate initial treatment for these patients.
Authors
- Hwa Jung Kim (ORCID: https://orcid.org/0000-0003-1916-7014)
- Jihye Lim (ORCID: https://orcid.org/0000-0002-1878-0215)
- Jonggi Choi (ORCID: https://orcid.org/0000-0002-7470-5850)
- Ye‐Jee Kim (ORCID: https://orcid.org/0000-0002-3307-2970)
- Jiwon Yang (ORCID: https://orcid.org/0009-0002-1577-1759)
Institutions
- Ulsan College (KR)
- Asan Medical Center (KR)
- University of Ulsan (KR)
- The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
Publication Details
- Journal
- Liver International
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1111/liv.70357
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00